



April 28, 2023

Philips Medical Systems, Nederland B.V.  
% Ioana Ulea  
Senior Regulatory Affairs Specialist  
Veenpluis 4-6  
Best, 5684 PC  
Netherlands

Re: K230972

Trade/Device Name: Ingenia Elition and MR 7700 MR Systems  
Regulation Number: 21 CFR 892.1000  
Regulation Name: Magnetic Resonance Diagnostic Device  
Regulatory Class: Class II  
Product Code: LNH, LNI  
Dated: April 5, 2023  
Received: April 5, 2023

Dear Ioana Ulea:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal

statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email ([DICE@fda.hhs.gov](mailto:DICE@fda.hhs.gov)) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

A handwritten signature in black ink, appearing to read 'D. Krainak', is written over a light blue watermark of the FDA logo.

Daniel M. Krainak, Ph.D.  
Assistant Director  
Magnetic Resonance and Nuclear Medicine Team  
DHT8C: Division of Radiological Imaging  
and Radiation Therapy Devices  
OHT8: Office of Radiological Health  
Office of Product Evaluation and Quality  
Center for Devices and Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known)  
K230972

Device Name  
Ingenia Elition and MR 7700 MR Systems

### Indications for Use (Describe)

Philips Magnetic Resonance (MR) systems are Medical Electrical Systems indicated for use as a diagnostic device. This MR system enables trained physicians to obtain cross-sectional images, spectroscopic images and/or spectra of the internal structure of the head, body or extremities, in any orientation, representing the spatial distribution of protons or other nuclei with spin.

Image appearance is determined by many different physical properties of the tissue and the anatomy, the MR scan technique applied, and presence of contrast agents. The use of contrast agents for diagnostic imaging applications should be performed consistent with the approved labeling for the contrast agent.

The trained clinical user can adjust the MR scan parameters to customize image appearance, accelerate image acquisition, and synchronize with the patient's breathing or cardiac cycle.

The systems can use combinations of images to produce physical parameters, and related derived images. Images, spectra, and measurements of physical parameters, when interpreted by a trained physician, provide information that may assist diagnosis and therapy planning. The accuracy of determined physical parameters depends on system and scan parameters, and must be controlled and validated by the clinical user.

In addition the Philips MR systems provide imaging capabilities, such as MR fluoroscopy, to guide and evaluate interventional and minimally invasive procedures in the head, body and extremities. MR Interventional procedures, performed inside or adjacent to the Philips MR system, must be performed with MR Conditional or MR Safe instrumentation as selected and evaluated by the clinical user for use with the specific MR system configuration in the hospital. The appropriateness and use of information from a Philips MR system for a specific interventional procedure and specific MR system configuration must be validated by the clinical user.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

**\*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\***

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services  
Food and Drug Administration  
Office of Chief Information Officer  
Paperwork Reduction Act (PRA) Staff  
[PRASStaff@fda.hhs.gov](mailto:PRASStaff@fda.hhs.gov)

*"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."*

## 510(k) Summary of Safety and Effectiveness

This 510(k) summary of safety and effectiveness information is prepared in accordance with 21 CFR §807.92.

<b>Date Prepared:</b>	April. 05, 2023	
<b>Manufacturer:</b>	Philips Medical Systems Nederland B.V. Veenpluis 6, 5684 PC, Best, The Netherlands Establishment Registration Number: 3003768277	
<b>Primary Contact Person:</b>	Ioana Ulea Senior Regulatory Affairs Specialist Phone: +31 618345875 E-mail: <a href="mailto:ioana.ulea@philips.com">ioana.ulea@philips.com</a>	
<b>Secondary Contact Person</b>	Jan van de Kerkhof Associate Director Regulatory Affairs Phone: +31 613300542 E-mail: <a href="mailto:jan.van.de.kerkhof@philips.com">jan.van.de.kerkhof@philips.com</a>	
<b>Device Name:</b>	<b>Ingenia Elition and MR 7700 MR Systems</b>	
<b>Classification:</b>	Classification name:	Magnetic Resonance Diagnostic Device (MRDD)
	Classification Regulation:	21CFR 892.1000
	Classification Panel:	Radiology
	Device Class:	Class II
	Primary Product Code:	90LNH 90LNI
<b>Primary Predicate Device:</b>	Trade name:	<i>MR 5300 and MR 7700 R11 MR Systems</i>
	Manufacturer:	Philips Medical Systems Nederland B.V.
	510(k) Clearance:	K223442
	Classification Regulation:	21CFR 892.1000
	Classification name:	Magnetic Resonance Diagnostic Device (MRDD)
	Classification Panel:	Radiology
	Device class	Class II
Product Code:	90LNH 90LNI	
<b>Secondary Predicate Device:</b>	Trade name:	<i>Achieva, Ingenia, Ingenia CX, Ingenia Elition and Ingenia Ambition MR Systems R11</i>
	Manufacturer:	Philips Medical Systems Nederland B.V.
	510(k) Clearance:	K213583
	Classification Regulation:	21CFR 892.1000

	Classification name:	Magnetic Resonance Diagnostic Device (MRDD)
	Classification Panel:	Radiology
	Device class	Class II
	Product Code:	90LNH 90LNI

<p><b>Device Description:</b></p>	<p>This Special 510(k) submission will include modifications of the proposed <b>Ingenia Elition and MR 7700 MR Systems</b> as compared to Philips legally marketed devices, primary predicate device MR 7700 R11 MR System of the 510(k) submission <i>MR 5300 and MR 7700 R11 MR Systems (K223442, 12/23/2022)</i> as well as the secondary predicate device being the legally marketed Ingenia Elition R11 MR System of the 510(k) submission <i>Achieva, Ingenia, Ingenia CX, Ingenia Elition and Ingenia Ambition MR Systems R11 (K213583, 04/15/2022)</i>.</p> <p>In this 510(k) submission, Philips Medical Systems Nederland B.V. will be addressing the following minor hardware enhancements for the proposed <b>Ingenia Elition and MR 7700 MR Systems</b> since the last 510(k) submission (<i>K223442, 12/23/2022</i>) for each of the systems:</p> <ol style="list-style-type: none"> <li>1. The SmokeDetector Interlock, a component used in the legally marketed Ingenia Elition and MR 7700 systems, becomes a mandatory risk control measure.</li> <li>2. Minor design change to current gradient coil type WB30S</li> </ol> <p>Identical to the predicate devices, the proposed <b>Ingenia Elition and MR 7700 MR Systems</b> are intended to be marketed with the following pulse sequences and coils that are previously cleared by FDA:</p> <ol style="list-style-type: none"> <li>1. mDIXON (K102344)</li> <li>2. SWIp (K131241)</li> <li>3. mDIXON-Quant (K133526)</li> <li>4. MRE (K140666)</li> <li>5. mDIXON XD (K143128)</li> <li>6. O-MAR (K143253)</li> <li>7. 3D APT (K172920)</li> <li>8. Compatible System Coils (identical to the predicate devices)</li> </ol>
<p><b>Indications for Use:</b></p>	<p>There are no changes to the indications for use statement, provided below, of the proposed <b>Ingenia Elition and MR 7700 MR Systems</b> when compared to the primary predicate device <i>MR 5300 and MR 7700 R11 MR Systems (K223442, 12/23/2022)</i> and secondary predicate device <i>Achieva, Ingenia, Ingenia CX, Ingenia Elition and Ingenia Ambition MR Systems R11 (K213583, 04/15/2022)</i>:</p>

	<p><i>“Philips Magnetic Resonance (MR) systems are Medical Electrical Systems indicated for use as a diagnostic device.</i></p> <p><i>This MR system enables trained physicians to obtain cross-sectional images, spectroscopic images and/or spectra of the internal structure of the head, body or extremities, in any orientation, representing the spatial distribution of protons or other nuclei with spin.</i></p> <p><i>Image appearance is determined by many different physical properties of the tissue and the anatomy, the MR scan technique applied, and presence of contrast agents.</i></p> <p><i>The use of contrast agents for diagnostic imaging applications should be performed consistent with the approved labeling for the contrast agent.</i></p> <p><i>The trained clinical user can adjust the MR scan parameters to customize image appearance, accelerate image acquisition, and synchronize with the patient’s breathing or cardiac cycle. The systems can use combinations of images to produce physical parameters, and related derived images. Images, spectra, and measurements of physical parameters, when interpreted by a trained physician, provide information that may assist diagnosis and therapy planning. The accuracy of determined physical parameters depends on system and scan parameters and must be controlled and validated by the clinical user.</i></p> <p><i>In addition, the Philips MR systems provide imaging capabilities, such as MR fluoroscopy, to guide and evaluate interventional and minimally invasive procedures in the head, body and extremities. MR Interventional procedures, performed inside or adjacent to the Philips MR system, must be performed with MR Conditional or MR Safe instrumentation as selected and evaluated by the clinical user for use with the specific MR system configuration in the hospital. The appropriateness and use of information from a Philips MR system for a specific interventional procedure and specific MR system configuration must be validated by the clinical user”.</i></p>
<p><b>Design Features/ Fundamental Scientific Technology:</b></p>	<p>Same as the predicate devices, the proposed <b>Ingenia Elition and MR 7700 MR Systems</b> are based on the principle that certain atomic nuclei present in the human body will emit a weak relaxation signal when placed in a strong magnetic field and excited by a radio signal at the precession frequency. The emitted relaxation signals are analyzed by the system and a computed image reconstruction is displayed on a video screen.</p> <p>The principal technological components (magnet, transmit body coil, gradient coil, gradient amplifier, RF amplifier and patient support) of the proposed <b>Ingenia Elition and MR 7700 MR Systems</b> are fundamentally the same as those used in the legally marketed primary predicate device <i>MR 5300 and MR 7700 R11 MR Systems (K223442, 12/23/2022)</i> and secondary predicate device <i>Achieva, Ingenia, Ingenia CX, Ingenia Elition</i></p>

	<p>and <i>Ingenia Ambition MR Systems R11 (K213583, 04/15/2022)</i>. The gradient coil has a minor modification which does not affect the technological characteristics of the gradient coil.</p>			
<p><b>Summary of Non-Clinical Performance Data:</b></p>	<p>The proposed <b>Ingenia Elition and MR 7700 MR Systems</b> are in compliance with the following international and FDA-recognized consensus standards:</p>			
	No.	Recognition Number	Standard Number and Date	Standard Name
	1	12-295	IEC60601-2-33 Ed. 3.2:2010 + Amd 1:2013 + Amd 2:2015	<i>Medical electrical equipment - Part 2-33: Particular requirements for the basic safety and essential performance of magnetic resonance equipment for medical diagnosis</i>
	2	19-4	ANSI / AAMI ES60601-1:2005/(R)2012 and A1:2012	<i>Medical Electrical Equipment - Part 1: General Requirements For Basic Safety And Essential Performance (IEC 60601-1:2006, MOD).</i>
	3	19-8	IEC60601-1-2 Ed. 4.0:2014	<i>Medical electrical equipment - Part 1-2: General requirements for basic safety and essential performance - Collateral standard: Electromagnetic disturbances - Requirements and tests</i>
	4	5-89	IEC 60601-1-6 Ed. 3.1:2010 + Amd 1:2013	<i>Medical electrical equipment - Part 1-6: General requirements for basic safety and essential performance - Collateral Standard: Usability</i>
	5	5-76	IEC 60601-1-8 Ed. 2.1:2006 + Amd 1:2012 (Ed.2.1)	<i>Medical electrical equipment - Part 1-8: General requirements for basic safety and essential performance - Collateral Standard: General requirements, tests and guidance for alarm systems in medical electrical equipment and medical electrical systems</i>
	6	5-125	ISO 14971 Third Edition 2019	<i>Medical devices – Application of risk management to medical devices.</i>
	7	5-114	IEC 62366-1 Ed. 1.0:2015	<i>Medical devices – Part 1: Application of usability engineering to medical devices</i>
	8	13-79	IEC 62304 Ed. 1.1:2015	<i>Medical device software – Software life cycle processes.</i>
<p>Non-Clinical verification tests have been performed with regards to the requirement specifications and the risk management results.</p> <p>The verification test results demonstrate that the proposed <b>Ingenia Elition and MR 7700 MR Systems</b> meet the acceptance criteria and are adequate for the intended use.</p>				

	<p>The validation testing performed with the primary and secondary predicate devices remain valid for the changes introduced with the proposed device <b>Ingenia Elition and MR 7700 MR Systems</b>.</p> <p>Additionally, the risk management activities show that all risks are sufficiently mitigated; that new risks that were identified are mitigated to an acceptable level; and that the overall residual risk is acceptable.</p> <p>Therefore, the proposed <b>Ingenia Elition and MR 7700 MR Systems</b> are substantially equivalent to the legally marketed primary predicate device <i>MR 5300 and MR 7700 R11 MR Systems (K223442, 12/23/2022)</i> and secondary predicate device <i>Achieva, Ingenia, Ingenia CX, Ingenia Elition and Ingenia Ambition MR Systems R11 (K213583, 04/15/2022)</i>, in terms of safety and effectiveness.</p>
<p><b>Summary of Clinical Data:</b></p>	<p>The proposed <b>Ingenia Elition and MR 7700 MR Systems</b> did not introduce any modification to the indication for use or technological characteristics relative to the predicate devices that would require clinical testing.</p>
<p><b>Substantial Equivalence:</b></p> <p><b>Conclusion:</b></p>	<p>The proposed <b>Ingenia Elition and MR 7700 MR Systems</b> and the legally marketed primary predicate device <i>MR 5300 and MR 7700 R11 MR Systems (K223442, 12/23/2022)</i> and secondary predicate device <i>Achieva, Ingenia, Ingenia CX, Ingenia Elition and Ingenia Ambition MR Systems R11 (K213583, 04/15/2022)</i>, have the same indications for use with respect to the following:</p> <ul style="list-style-type: none"> <li>• Providing cross-sectional images based on the magnetic resonance phenomenon</li> <li>• Interpretation of the images is the responsibility of trained physicians</li> <li>• Images can be used for interventional and treatment planning purposes</li> </ul> <p>The proposed <b>Ingenia Elition and MR 7700 MR Systems</b> are substantially equivalent to the legally marketed primary predicate device <i>MR 5300 and MR 7700 R11 MR Systems (K223442, 12/23/2022)</i> and secondary predicate device <i>Achieva, Ingenia, Ingenia CX, Ingenia Elition and Ingenia Ambition MR Systems R11 (K213583, 04/15/2022)</i>, in terms of design features, fundamental scientific technology, indications for use, and safety and effectiveness.</p> <p>Additionally, substantial equivalence is demonstrated with non-clinical performance tests and compliance with the requirements specified in the international and FDA-recognized consensus standards and device-specific guidance.</p> <p>The results of these tests demonstrate that the proposed <b>Ingenia Elition and MR 7700 MR Systems</b> meet the acceptance criteria and are adequate for the intended use.</p>